SCHEDULE: Deep Track Capital Discloses 7.34% Stake in Century Therapeutics

Deep Track Capital and its affiliated funds have reported a passive beneficial ownership of 7.34% in Century Therapeutics, Inc., totaling 13,486,400 shares.

Summary

• Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., David Kroin, and Deep Track Special Opportunities Fund, LP, collectively reported beneficial ownership of 13,486,400 shares of Century Therapeutics, Inc. common stock.
• This aggregate ownership represents 7.34% of the company's outstanding common stock.
• The reported shares include 4,347,826 warrants exercisable into common stock, subject to a 9.99% maximum exercise limitation.
• The calculation of the percentage of class is based on 183,685,512 total shares, which includes common stock outstanding as of November 1, 2025 (87,307,091 shares), common stock issued as of January 8, 2026 (92,030,595 shares), and the 4,347,826 warrants convertible by the reporting person up to the maximum percentage.
• The acquisition of these securities was not for the purpose of changing or influencing the control of Century Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The filing reports a significant passive institutional investment, which is generally a positive signal for the company, indicating confidence from a specialized fund. However, it's a factual ownership disclosure rather than a performance update, so the sentiment is moderately positive due to the implied vote of confidence.

Positives

• Increased institutional ownership by Deep Track Capital, a specialized investment firm, may signal confidence in Century Therapeutics, Inc.
• The significant stake of 7.34% indicates a substantial investment by the reporting group.

Negatives

• The 9.99% maximum percentage exercise limitation on warrants could restrict the immediate full conversion of all held warrants, potentially limiting the reporting person's flexibility.

Risks

• The exercise of warrants is subject to a 9.99% maximum percentage limitation, meaning the holder cannot exercise warrants if it would result in beneficial ownership exceeding 9.99% of the outstanding common stock immediately after exercise.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment in Century Therapeutics, Inc., a biotechnology company. Such investments are common in the biotech sector, where specialized funds like Deep Track Capital seek opportunities in companies with promising pipelines or technologies. A substantial passive stake can be viewed positively by the market, suggesting external validation of the company's potential.

Stakeholder Impact

• Shareholders: May view the significant institutional investment as a positive signal, potentially increasing investor confidence and demand for the stock.
• Company Management: The presence of a large passive investor could lead to increased scrutiny or engagement, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

Century Therapeutics, Deep Track Capital, Beneficial Ownership, Schedule 13G, Biotechnology, Institutional Investment, Common Stock, Warrants, Passive Investment